GlassScriptPhysician profile
Nakeetsha Dryer
NPI 1518217876
$9,027.94
in general payments reported to CMS, 2019-2025
30 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,583 · 2022: $1,840 · 2023: $1,816 · 2024: $2,003 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,604.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,533.95 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,335.44 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,129.57 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $783.99 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $773.86 | 2021-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Alkermes, INC. | $668.85 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $603.18 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $304.80 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $230.85 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $218.32 | 2021-2025 | Fanapt |
| Corium, LLC | $213.75 | 2022-2025 | Azstarys |
| Tris Pharma INC | $178.37 | 2022-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Braeburn INC. | $170.33 | 2025 | Brixadi |
| Indivior INC. | $119.80 | 2024 | Sublocade |
| Eisai INC. | $114.23 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $90.39 | 2021-2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $83.84 | 2021-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $80.22 | 2021 | |
| Bausch Health US, LLC | $66.26 | 2021-2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $45.45 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $44.43 | 2023-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $40.77 | 2023-2025 | Austedo, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $35.83 | 2021-2023 | Qelbree |
| Adlon Therapeutics L.P. | $34.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.28 | 2022-2023 | Quviviq |
| Pear Therapeutics (US), INC. | $22.15 | 2021 | |
| Noven Therapeutics, LLC | $21.31 | 2024 | Xelstrym |
| Merck Sharp & Dohme LLC | $17.33 | 2021 | |
| Orexo US, INC. | $16.39 | 2021 | |
| Alfasigma USA, INC. | $15.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nakeetsha Dryer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.